The Lumipulse G β-Amyloid Ratio (1-42/1-40) test is available at clinical laboratories nationwide for adult patients aged 55 years and older who are presenting with cognitive impairment and being evaluated for Alzheimer’s disease and other causes of cognitive decline.
The test, which is developed by Fujirebio Diagnostics Inc., is intended to measure the ratio of β-amyloid 1-42 and β-amyloid 1-40 proteins found in human cerebral spinal fluid, which can help physicians determine whether a patient is likely to have amyloid plaques. β-amyloid plaques are believed to contribute to the loss of cognitive function that characterizes Alzheimer's disease.
Prior to the marketing authorization, doctors used positron emission tomography scans, a potentially costly and time-consuming option, to detect and visualize amyloid plaques in a patient’s brain and help diagnose Alzheimer's disease years before clinical symptom onset.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
FDA Clears Diagnostic Test for Early Alzheimer'sThe FDA has cleared the first lab diagnostic test to aid in the early detection of Alzheimer's disease.
Weiterlesen »
Annual COVID-19 shot could be necessary, FDA officials sayWe may need to get a COVID-19 vaccine every year, the same way we do with the flu shot.
Weiterlesen »
A drug firm in Bucks County that sold FDA-approved generics had big plans to grow. Now it faces charges of misleading the FDADaily News | A drug firm in Bucks County that sold FDA-approved generics had big plans to grow. Now it faces charges of misleading the FDA
Weiterlesen »
FDA puts strict limits on Johnson & Johnson Covid-19 vaccineThe US Food and Drug Administration announced Thursday that it is limiting the emergency use authorization of the Johnson & Johnson/Janssen Covid-19 vaccine to people 18 and older for whom other vaccines aren't appropriate or accessible and those who opt for J&J because they wouldn't otherwise get vaccinated.
Weiterlesen »
FDA restricts J&J's COVID-19 vaccine due to blood clot riskThe Food and Drug Administration said the shot should only be given to adults who cannot receive a different vaccine or specifically request J&J's vaccine.
Weiterlesen »
FDA restricts J&J's COVID-19 vaccine due to blood clot riskWASHINGTON (AP) — U.S. regulators on Thursday strictly limited who can receive Johnson & Johnson’s COVID-19 vaccine due to a rare but serious risk of blood clots. The Food and Drug Administration said the shot should only be given to adults who cannot receive a different vaccine or specifically request J&J's vaccine.
Weiterlesen »